Claims for Patent: 6,602,911

Summary for Patent: 6,602,911

Title:	Methods of treating fibromyalgia
Abstract:	The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s):	Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee:	Cypress Bioscience, Inc. (San Diego, CA)
Application Number:	10/028,547
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,602,911
Patent Claims:	1. A method of treating fibromyalgia syndrome (FMS) comprising administering to an animal subject suffering from FMS, a composition wherein the active ingredient consists of milnacipran, or a pharmaceutically acceptable salt thereof in an amount effective to treat the chronic pain and fatigue associated with FMS. 2. The method according to claim 1, wherein the animal subject is a human. 3. The method according to claim 1, wherein the amount of milnacipran administered is from about 25 mg to about 400 mg per day. 4. The method according to claim 1, wherein the milnacipran is formulated in a sustained release dosage formulation. 5. The method of claim 1 wherein the amount of milnacipran administered is at least 100 mg per day. 6. The method of claim 1 wherein the amount of milnacipran administered is between 100 and 400 mg per day. 7. The method of claim 1 wherein the amount of milnacipran administered is between 100 and 250 mg per day.